AR111830A1 - Anticuerpos monoclonales antagonistas contra cd40 y sus usos - Google Patents
Anticuerpos monoclonales antagonistas contra cd40 y sus usosInfo
- Publication number
- AR111830A1 AR111830A1 ARP180101388A ARP180101388A AR111830A1 AR 111830 A1 AR111830 A1 AR 111830A1 AR P180101388 A ARP180101388 A AR P180101388A AR P180101388 A ARP180101388 A AR P180101388A AR 111830 A1 AR111830 A1 AR 111830A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- antigen binding
- binding portion
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La descripción proporciona anticuerpos que se fijan a CD40, que incluye un anticuerpo humanizado y un anticuerpo quimérico con dominios Fc diferentes. Los anticuerpos se fijan a CD40 y no exhiben actividad agonista de CD40. Los anticuerpos pueden comprender un dominio Fc de IgG1 modificado y exhibir activación mínima de células dendríticas inmaduras. Composiciones que comprenden anticuerpos, métodos de uso para el tratamiento de enfermedades que incluyen la actividad de CD40, y el uso en la preparación de un medicamento para el tratamiento de una enfermedad que incluye la actividad de CD40. Reivindicación 1: Un anticuerpo aislado, o una porción de fijación al antígeno de este, que se fija específicamente a CD40 humana, en donde dicho anticuerpo comprende una cadena pesada y una cadena liviana, caracterizado porque: dicha cadena pesada comprende una CDR1 que comprende GYTFTDLSMHW (SEQ ID Nº 1), una CDR2 que comprende YITPSSGYTAYNQKFKG (SEQ ID Nº 2), una CDR3 que comprende LILQRGAY (SEQ ID Nº 3) y una región constante de la cadena pesada humana; y dicha cadena liviana comprende una CDR1 que comprende RASKNVDSYGNSFMHW (SEQ ID Nº 4), una CDR2 que comprende RASNLES (SEQ ID Nº 5), y una CDR3 que comprende QQSNEDPLT (SEQ ID Nº 6) y una región constante de la cadena liviana humana; y dicha región constante de la cadena pesada humana es un dominio Fc de IgG1 humana que comprende (1) una mutación en la posición 238 Kabat que reduce la fijación a los receptores Fc g (FcgR), en donde prolina 238 (P238) se muta a uno de los residuos seleccionados del grupo que consiste en lisina, serina, alanina, arginina y triptófano, y en donde el anticuerpo, o una porción de fijación al antígeno de este, tiene una fijación a FcgR reducida; o (2) una alanina sustituida en la posición 297 Kabat. Reivindicación 16: Un ácido nucleico caracterizado porque codifica un anticuerpo aislado, o una porción de fijación al antígeno de este, de acuerdo con cualquiera de las reivindicaciones 1 a 15. Reivindicación 17: Un vector de expresión caracterizado porque comprende la molécula del ácido nucleico de acuerdo con la reivindicación 16. Reivindicación 18: Una célula caracterizada porque está transformada con un vector de expresión de acuerdo con la reivindicación 17. Reivindicación 19: Un método para preparar un anticuerpo anti-CD40 humana, o una porción de fijación al antígeno de este, caracterizado porque comprende: a) expresar el anticuerpo, o la porción de fijación al antígeno de este, en la célula de acuerdo con la reivindicación 18; y b) aislar el anticuerpo, o una porción de fijación al antígeno de este, de la célula.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511079P | 2017-05-25 | 2017-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111830A1 true AR111830A1 (es) | 2019-08-21 |
Family
ID=62567875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101388A AR111830A1 (es) | 2017-05-25 | 2018-05-24 | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11220550B2 (es) |
| EP (1) | EP3630831B1 (es) |
| JP (1) | JP7257335B2 (es) |
| KR (1) | KR102713355B1 (es) |
| CN (1) | CN110621697B (es) |
| AR (1) | AR111830A1 (es) |
| ES (1) | ES2923143T3 (es) |
| TW (1) | TW201902934A (es) |
| WO (1) | WO2018217976A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913004UA (en) | 2014-11-21 | 2020-03-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| EP4371570A3 (en) | 2016-06-08 | 2024-07-17 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| KR20200012907A (ko) * | 2017-05-25 | 2020-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 |
| AR111830A1 (es) | 2017-05-25 | 2019-08-21 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| EP4098662A1 (en) * | 2017-05-25 | 2022-12-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| MA52190A (fr) | 2018-04-02 | 2021-02-17 | Bristol Myers Squibb Co | Anticorps anti-trem-1 et utilisations associées |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| US12247075B2 (en) * | 2018-12-26 | 2025-03-11 | Imcheck Therapeutics Sas | BTN3A binding proteins and uses thereof |
| WO2020159368A1 (en) * | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| LT4073098T (lt) * | 2019-12-19 | 2023-12-11 | Akston Biosciences Corporation | Itin ilgai veikiantys insulino-fc sulieti baltymai ir jų naudojimo būdai |
| EP4118118A1 (en) * | 2020-03-09 | 2023-01-18 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| CN113388035A (zh) * | 2020-03-13 | 2021-09-14 | 迈威(上海)生物科技股份有限公司 | 特异性针对人tslp的抗体及其应用 |
| JP7523586B2 (ja) * | 2020-05-18 | 2024-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 改善された薬物動態特性を有する抗体変異体 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB2353887B (en) | 1999-09-04 | 2003-09-24 | Ibm | Speech recognition system |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
| US20150315284A1 (en) | 2004-11-09 | 2015-11-05 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| EP1943332A4 (en) | 2005-10-14 | 2011-04-13 | Medimmune Inc | CELLULAR DISPLAY OF ANTIBODY LIBRARIES |
| AU2008207898B2 (en) | 2007-01-23 | 2012-05-03 | Xencor, Inc | Optimized CD40 antibodies and methods of using the same |
| AU2008247819B2 (en) | 2007-05-01 | 2013-02-14 | Research Development Foundation | Immunoglobulin Fc libraries |
| EA034136B1 (ru) | 2007-11-09 | 2020-01-09 | Перигрин Фармасьютикалз, Инк. | Изолированное антитело, которое связывается с vegf, и его применения |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| HUE038788T2 (hu) | 2010-03-31 | 2018-11-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| WO2012046745A1 (ja) | 2010-10-04 | 2012-04-12 | 独立行政法人理化学研究所 | Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP2655624B1 (en) * | 2010-12-23 | 2017-11-29 | Biogen MA Inc. | Linker peptides and polypeptides comprising same |
| CA2833743A1 (en) | 2011-04-21 | 2012-10-26 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize cd40 |
| KR20200096692A (ko) * | 2011-09-30 | 2020-08-12 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6226752B2 (ja) | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| RU2729831C2 (ru) | 2012-08-24 | 2020-08-12 | Чугаи Сейяку Кабусики Кайся | ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| GB201308658D0 (en) | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| HRP20191174T1 (hr) * | 2014-08-04 | 2019-10-04 | F. Hoffmann - La Roche Ag | Bispecifične molekule vezane na antigen koji aktivira t stanicu |
| US20170233485A1 (en) | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CN106687135A (zh) * | 2014-09-15 | 2017-05-17 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法 |
| SG10201913004UA (en) | 2014-11-21 | 2020-03-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| PT3303395T (pt) | 2015-05-29 | 2020-02-20 | Abbvie Inc | Anticorpos anti-cd40 e usos dos mesmos |
| EA035268B1 (ru) | 2015-06-29 | 2020-05-22 | Бристол-Маерс Сквибб Компани | Антитела к cd40 |
| UY36757A (es) | 2015-06-29 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada |
| EP3356532B1 (en) * | 2015-09-30 | 2022-01-19 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding human cd40 and methods of use |
| BR112019004938A2 (pt) | 2016-10-06 | 2019-06-25 | Glaxosmithkline Ip Dev Ltd | anticorpo igg4 variante, linhagem celular, métodos para modificação de um anticorpo igg para reduzir a ligação a uma impureza de processo e para produção de um anticorpo igg4 com ligação reduzida à proteína de célula hospedeira, e, composição. |
| US11603406B2 (en) | 2017-03-14 | 2023-03-14 | Five Prime Therapeutics, Inc. | Antibodies binding to VISTA at acidic pH |
| WO2018175279A2 (en) | 2017-03-20 | 2018-09-27 | The General Hospital Corporation | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY |
| EP4098662A1 (en) | 2017-05-25 | 2022-12-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| KR20200012907A (ko) | 2017-05-25 | 2020-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 |
| AR111830A1 (es) | 2017-05-25 | 2019-08-21 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN113348177A (zh) | 2018-11-28 | 2021-09-03 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
-
2018
- 2018-05-24 AR ARP180101388A patent/AR111830A1/es unknown
- 2018-05-24 EP EP18730621.2A patent/EP3630831B1/en active Active
- 2018-05-24 WO PCT/US2018/034315 patent/WO2018217976A1/en not_active Ceased
- 2018-05-24 ES ES18730621T patent/ES2923143T3/es active Active
- 2018-05-24 JP JP2019564883A patent/JP7257335B2/ja active Active
- 2018-05-24 KR KR1020197034230A patent/KR102713355B1/ko active Active
- 2018-05-24 CN CN201880030151.8A patent/CN110621697B/zh active Active
- 2018-05-24 US US15/988,554 patent/US11220550B2/en active Active
- 2018-05-25 TW TW107117879A patent/TW201902934A/zh unknown
-
2021
- 2021-12-23 US US17/561,529 patent/US11613585B2/en active Active
-
2023
- 2023-03-10 US US18/181,849 patent/US20230322941A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201902934A (zh) | 2019-01-16 |
| EP3630831A1 (en) | 2020-04-08 |
| JP2020521453A (ja) | 2020-07-27 |
| JP7257335B2 (ja) | 2023-04-13 |
| WO2018217976A1 (en) | 2018-11-29 |
| ES2923143T3 (es) | 2022-09-23 |
| KR20200011937A (ko) | 2020-02-04 |
| US11220550B2 (en) | 2022-01-11 |
| US20230322941A1 (en) | 2023-10-12 |
| US20220177596A1 (en) | 2022-06-09 |
| CN110621697B (zh) | 2023-06-27 |
| CN110621697A (zh) | 2019-12-27 |
| EP3630831B1 (en) | 2022-06-15 |
| US11613585B2 (en) | 2023-03-28 |
| US20180340031A1 (en) | 2018-11-29 |
| KR102713355B1 (ko) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| US20240076375A1 (en) | Anti-TIM-3 Antibodies and Use Thereof | |
| JP7345578B2 (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| CN112351820B (zh) | 双特异性抗psma x抗cd28抗体及其用途 | |
| KR102372274B1 (ko) | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 | |
| CN109843923B (zh) | 针对ctla-4的单结构域抗体及其变体 | |
| DK2976361T3 (en) | HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF | |
| JP2018520657A5 (es) | ||
| KR20250097989A (ko) | 공통 항원을 표적화하는 항원-결합 단백질 | |
| JP2022501377A (ja) | 血液悪性腫瘍の処置において使用するための新規の二重特異性抗体 | |
| KR20190095941A (ko) | 신규 tnfr 효능제 및 이의 용도 | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2017532037A (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| KR20200120641A (ko) | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| CN108368178A (zh) | 抗lag3抗体及其用途 | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| AR103442A1 (es) | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 | |
| ES2737307T3 (es) | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer | |
| EA202191359A1 (ru) | Антагонистические моноклональные антитела к cd40 и их применения | |
| US20220162320A1 (en) | Multispecific binding proteins | |
| JP7527281B2 (ja) | 抗体製剤 | |
| CN115925929A (zh) | 抗tnfr2单克隆抗体及其应用 | |
| JP2025156298A (ja) | 抗ニューヨーク食道扁平上皮がん１（ｎｙ－ｅｓｏ－１）抗原結合タンパク質およびその使用方法 | |
| CN112625130A (zh) | 抗-tigit抗体及使用之方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |